Clinical Trial Update: Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing pirfenidone and nintedanib for fibrotic lung disease following COVID-19 pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Novel Coronavirus-induced Lung Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)
• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh | Conditions: Novel Coronavirus-induced Lung Fibrosis | Phase 4 | Status: UNKNOWN